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Epstein-Barr Virus (EBV) is an exclusively human, lymphotropic herpes virus that infects 
more than 90% of the population worldwide. Primary infection usually occurs during the 
early years of life and does not result in any recognized disease. EBV is the causative 
agent of infectious mononucleosis and is associated with various malignancies including 
Burkitt’s lymphoma (BL), Hodgkin’s disease (HD), and nasopharyngeal carcinoma 
(NPC). In most immunocompetent individuals the virus is, however, harbored for life 
within latently infected resting memory B cells, causing no symptoms. In vitro, EBV 
efficiently transforms resting B cells to activated lymphoblasts that express a repertoire of 
viral antigens (EBNA1-6 and LMP1), all of which have been directly implicated in the 
immortalization process. Immediately post-infection, EBNA2 and -5 are expressed from 
the W promoter (Wp). Within 36 hours there is a switch in promoter usage from Wp to 
the upstream C promoter (Cp). Transcription from Cp leads to expression of all EBNAs 
from a polycistronic transcription unit that is spliced to yield the different EBNA proteins. 
EBNA1 forms multiple homodimers that bind to a portion of the latency origin of 
replication (oriPI) that functions as an EBNA1-dependent enhancer of Cp. The 
mechanism for the interaction between the oriPI-EBNA1 complex and the Cp is not 
completely understood at the molecular level. The aim of this thesis was to identify and 
characterize novel interaction partners in this macromolecular complex.  
The interactions of the transcription factors NF-Y and Sp1 with the Cp were previously 
established in our lab. In paper I we studied these interactions further using transient 
transfections, establishing that NF-Y and Sp1 co-stimulate Cp and that the oriPI-EBNA1-
induced transactivation of Cp requires concomitant expression of both proteins. 
Furthermore, using the lymphoblastoid cell line EREB2-5, in which EBNA2 function is 
regulated by estrogen, we demonstrated that inactivation of EBNA2 resulted in decreased 
expression of NF-Y and down-regulation of Cp. Knowing that resting B cells do not 
express NF-Y and observing that this factor is essential for Cp activation, we suggest that 
its up-regulation post-infection may contribute to the Wp-to-Cp switch in primary EBV 
infection. The oriPI contains 20 repeats of the EBNA1 binding domain. In paper II we 
used a series of oriPI-deletions in oriPI-CpCAT reporter plasmids in transient 
transfections, to determine the number of EBNA1 binding repeats necessary for efficient 
transactivation of the Cp. We showed that eight or more repeats are necessary for this 
effect, which underscores the complexity of the transactivation process. In papers III and 
IV we set out to identify novel interaction partners of the oriPI- and -170Cp regions using 
EMSA and DNA affinity purification coupled with mass spectrometry. Three novel 
protein interactions with the oriPI and the Cp were identified. The transcription factors 
Bright, E2F1 and Oct-2 were found to bind both sequences in vitro and in vivo, possibly 
linking the oriPI and the Cp. The binding sites of all three proteins were mapped to a 
short segment of Cp that is essential for both oriPI-dependent and -independent 
transcriptional activation, indicating that the interactions are important for Cp activity. In 
transient transfections, we demonstrated that exogenous Oct-2 or Bright expression up-
regulated oriPI-dependent Cp activation in the absence of EBNA1. Finally, endogenous 
Bright expression was shown to correlate with latency III but not latency I and II 
expression patterns in EBV positive cell lines, further supporting the notion that Bright 
expression is important for Cp transcriptional activity in vivo.
